BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 28212537)

  • 1. Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways.
    Liang G; Liu M; Wang Q; Shen Y; Mei H; Li D; Liu W
    Oncotarget; 2017 Apr; 8(17):28510-28525. PubMed ID: 28212537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.
    Hu Q; Hou YC; Huang J; Fang JY; Xiong H
    J Exp Clin Cancer Res; 2017 Apr; 36(1):50. PubMed ID: 28399898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways.
    Wang W; Dong X; Liu Y; Ni B; Sai N; You L; Sun M; Yao Y; Qu C; Yin X; Ni J
    Biomed Pharmacother; 2020 Nov; 131():110661. PubMed ID: 32942154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
    Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
    Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itraconazole Modulates Hedgehog, WNT/β-catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells.
    Ueda T; Tsubamoto H; Inoue K; Sakata K; Shibahara H; Sonoda T
    Anticancer Res; 2017 Jul; 37(7):3521-3526. PubMed ID: 28668841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
    Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
    Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog inhibitor sonidegib potentiates
    Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
    BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
    J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
    Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
    Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
    Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
    Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
    Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
    PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways.
    Lim HN; Baek SB; Jung HJ
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30866426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
    Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
    Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.